In this study, we aimed to determine whether the pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) in plasma could be used as a novel approach to screen for and detect hepatocellular carcinoma (HCC). We explored the clinical role of INTS6P1: First, the expression level of INTS6P1 was measured in a cohort of 33 HCC tissue samples and adjacent normal liver tissue, next, the INTS6P1 expression was detected in the culture medium and tumor cells in a cellular experiment, and last, the diagnostic performance of INTS6P1 was examined in an independent cohort of 100 people. The expression level of INTS6P1 was remarkably downregulated in the HCC tissues compared with that in the normal liver tissues (p = 0.0066). In plasma, the INTS6P1 levels were significantly decreased in HCC patients compared with non-HCC patients (p < 0.01). Additionally, we inferred that INTS6P1 might be a prospective biomarker for screening HCC patients in which the serum-AFP levels were lower than 20 ng/ml by the area under the curve-receiver operating characteristic (AUC-ROC) analysis (p < 0.05). Pseudogene INTS6P1 could be used as a novel HCC plasma-based biomarker and might improve the accuracy of HCC screening.
This is a preview of subscription content, log in to check access
This study was supported by the National Natural Science Foundation of China (Grant No. 81170450) and International Program for Ph.D. Candidates, Sun Yat-sen University. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. None of the information in this manuscript has been presented in any meeting or conference.
Ka Yin Lui and Jin-rong Lin performed the experiments. Hao-ran Peng, Chun-hui Qiu, Hu-an Chen, and Rong-dang Fu analyzed the data. Ka Yin Lui wrote the manuscript. Chang-jie Cai and Min-qiang Lu conceived and designed the experiments. All authors read and approved the final manuscript.
Compliance with ethical requirements
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5). Informed consent was obtained from all patients for being included in the study. The Third Affiliated Hospital of Sun Yat-sen University Ethics Committee approved the study, and all involved patients gave written informed consent for their clinical data and samples (blood, serum) to be used in this study. Human experimentation guidelines of P.R. China were followed in the conduct of this research.
Conflicts of interest
Ka Yin Lui, Hao-ran Peng, Jin-rong Lin, Chun-hui Qiu, Hu-an Chen, Rong-dang Fu, Chang-jie Cai, and Min-qiang Lu declare that they have no conflict of interest
Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237(4):536–43.PubMedPubMedCentralGoogle Scholar
Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4(7):424–32.CrossRefPubMedGoogle Scholar
Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology. 2012;55:1416–25.CrossRefPubMedGoogle Scholar
El-Aneed A, Banoub J. Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients. Anticancer Res. 2006;26(5A):3293–300.PubMedGoogle Scholar
Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003;37(5):1114–21.CrossRefPubMedGoogle Scholar
Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–48.CrossRefPubMedGoogle Scholar
Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer. 1989;64(10):2117–20.CrossRefPubMedGoogle Scholar
Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, Yu JY, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer. 1985;56(3):660–6.CrossRefPubMedGoogle Scholar
Song ZZ. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47(6):2145–56.CrossRefPubMedGoogle Scholar
Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37.CrossRefPubMedGoogle Scholar
Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 2011;472:120–4.CrossRefPubMedPubMedCentralGoogle Scholar
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.CrossRefPubMedGoogle Scholar
Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013; 10.Google Scholar
Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38:5366–83.CrossRefPubMedPubMedCentralGoogle Scholar
Tian Y, Yang W, Song J, Wu Y, Ni B. Hepatitis B virus x protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol. 2013;33:2810–6.CrossRefPubMedPubMedCentralGoogle Scholar
He Y, Meng X-M, Huang C, Wu B-M, Zhang L, Lv X-W, et al. Long noncoding RNAs: novel insights into hepatocelluar carcinoma. Cancer Lett. 2014;344:20–7.CrossRefPubMedGoogle Scholar
Peng H, Ishida M, Li L, Saito A, et al. Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget. 2015;6(8):5666–77.CrossRefPubMedPubMedCentralGoogle Scholar
Liu R, Chen X, Du Y, et al. SerummicroRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58:610–8.CrossRefPubMedGoogle Scholar
Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–59.CrossRefPubMedGoogle Scholar